Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2002

Conditions
Neurofibromatosis Type 1Precancerous Condition
Interventions
DRUG

pirfenidone

Trial Locations (15)

10128

Beth Israel Medical Center - Singer Division, New York

13210

University Hospital at State University of New York - Upstate Medical University, Syracuse

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

20892

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

21231

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

55905

Mayo Clinic Cancer Center, Rochester

60614

Children's Memorial Hospital - Chicago, Chicago

63110

Washington University School of Medicine, St Louis

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

20010-2970

Children's National Medical Center, Washington D.C.

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

97239-3098

Cancer Institute at Oregon Health and Science University, Portland

77030-2399

Texas Children's Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00053937 - Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas | Biotech Hunter | Biotech Hunter